5-[5-(4-methyl-1,3-thiazol-2-yl)-2H-triazol-4-yl]-2,1,3-benzothiadiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-[5-(4-methyl-1,3-thiazol-2-yl)-2H-triazol-4-yl]-2,1,3-benzothiadiazole
• 化学式: C₁₂H₈N₆S₂
• 分子量: 300.4
• InChiKey: OOEYBSIRRZDYKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  137
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Thiazolyl substituted triazoles as alk5 inhibitors
  申请人：——

  公开号：US20040266842A1

  公开（公告）日：2004-12-30

  Thiazolyl substituted triazoles of formula (I) 1 wherein R 1 is naphthyl or phenyl optionally substituted with one or more substituents selected from halo, —O—C 1-6 alkyl, —S—C 1-6 alkyl, C 1-6 alkyl, C 1-6 haloalkyl, —O—(CH 2 ) n —Ph, —S—(CH 2 ) n —Ph, cyano, phenyl, and CO 2 R, wherein R is hydrogen or C 1-6 alkyl, and n is 0, 1, 2 or 3; or R 1 is phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S, and N may be further optionally substituted by C 1-6 alkyl, and wherein the cyclic ring may be optionally substituted by ═O; or R 1 is pyridyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S, and N may be further optionally substituted by C 1-6 alkyl, and wherein the cyclic ring may be optionally substituted by ═O; R 2 is H, C 1-6 alkyl, C 1-6 alkoxy, phenyl, NH(CH 2 ) n —Ph, NH—C 1-6 alkyl, halo, CN, NO 2 , CONHR and SO 2 NHR; two of X 1 , X 2 and X 3 are N and the other is NR 3 wherein R 3 is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, —(CH 2 ) p —CN, —(CH 2 ) p —CO 2 H, —(CH 2 ) p —CONHR 4 R 5 , —(CH) p COR 4 , —(CH 2 ) q (OR 6 ) 2 , —(CH 2 ) p OR 4 , —(CH 2 ) q CH═CH—CN, —(CH 2 ) q —CH═CH—CO 2 H, —(CH 2 ) p —CH═CH—CONHR 4 R 5 , —(CH 2 ) p NHCOR 7 or —(CH 2 ) p NR 8 R 9 ; R 4 and R 5 are independently hydrogen or C 1-6 alkyl; R 6 is C 1-6 alkyl; R 7 is C 1-7 alkyl, or optionally substituted aryl, heteroaryl, arylC 1-6 alkyl or heteroarylC 1-6 alkyl; R 8 and R 9 are independently selected from hydrogen, C 1-6 alkyl, aryl and arylC 1-6 alkyl; p is 0-4; and q is 1-4 and salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine.

  公式（I）中的噻唑基取代的三唑化合物1，其中R1是萘基或苯基，可选地取代一种或多种取代基，所选取代基包括卤素，—O—C1-6烷基，—S—C1-6烷基，C1-6烷基，C1-6卤代烷基，—O—（CH2）n—Ph，—S—（ ）n—Ph，氰基，苯基和CO2R，其中R是氢或C1-6烷基，n为0，1，2或3；或者R1是与5-7个成员的芳香或非芳香环状环融合的苯基，所述环状环可选地包含高达三个杂原子，独立选择自N，O和S，其中N可以进一步选自C1-6烷基取代，环状环可以可选地被═O取代；或者R1是与5-7个成员的芳香或非芳香环融合的吡啶基，所述环状环可选地包含高达三个杂原子，独立选择自N，O和S，其中N可以进一步选自C1-6烷基取代，环状环可以可选地被═O取代；R2是H，C1-6烷基，C1-6烷氧基，苯基，NH（ ）n—Ph，NH—C1-6烷基，卤素，CN，NO2，CONHR和SO2NHR；X1、X2和X3中的两个是N，另一个是NR3，其中R3是氢，C1-6烷基，C3-7环烷基，—（ ）p—CN，—（ ）p—CO2H，—（ ）p—CONHR4R5，—（CH）pCOR4，—（ ）q（OR6）2，—（ ）pOR4，—（ ）qCH═CH—CN，—（ ）q—CH═CH—CO2H，—（ ）p—CH═CH—CONHR4R5，—（ ）pNHCOR7或—（ ）pNR8R9；R4和R5独立选择自氢或C1-6烷基；R6是C1-6烷基；R7是C1-7烷基，或可选地取代芳基，杂芳基，芳基C1-6烷基或杂芳基C1-6烷基；R8和R9独立选择自氢，C1-6烷基，芳基和芳基C1-6烷基；p为0-4；q为1-4及其盐和溶剂化合物，以及它们的制备方法，包含它们的药物组合物以及它们在医学上的使用。
• THIAZOLYL SUBSTITUTED TRIAZOLES AS ALK5 INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP1444227A1

  公开（公告）日：2004-08-11
• [EN] THIAZOLYL SUBSTITUTED TRIAZOLES AS ALK5 INHIBITORS<br/>[FR] TRIAZOLES A SUBSTITUANT THIAZOLYLE UTILISES COMME INHIBITEURS DE ALK5
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003042207A1

  公开（公告）日：2003-05-22

  Thiazolyl substituted triazoles of formula (I) wherein R1 is naphthyl or phenyl optionally substituted with one or more substituents selected from halo, -O-C1-6-alkyl, -S-C1-6alkyl, C1-6alkyl, C1-6haloalkyl, -O-(CH2) n-Ph, -S-(CH2) n-Ph, cyano, phenyl, and CO2R, wherein R is hydrogen or C1-6alkyl, and n is 0, 1, 2 or 3; or R1 is phenyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S, and N may be further optionally substituted by C1-6alkyl, and wherein the cyclic ring may be optionally substituted by =O; or R1 is pyridyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S, and N may be further optionally substituted by C1-6alkyl, and wherein the cyclic ring may be optionally substituted by =O; R2 is H, C1-6alkyl, C1-6alkoxy, phenyl, NH(CH2)n-Ph, NH-C1-6alkyl, halo, CN, NO2, CONHR and SO2NHR; two of X1, X2 and X3 are N and the other is NR3 wherein R3 is hydrogen, C1-6 alkyl, C3-7cycloalkyl, -(CH2)p-CN, -(CH2)p-CO2H, -(CH2)p-CONHR4R5, -(CH2)pCOR4, -(CH2)q(OR5)2, -(CH2)pOR4, -(CH2)q-CH=CH-CN, -(CH2) q-CH=CH-CO2H, -(CH2)P-CH=CH-CONHR4R5, -(CH2)PNHCOR 7 or -(CH2)PNR8R9; R4 and R5 are independently hydrogen or C1-6alkyl; R6 is C1-6alkyl; R7 is C1-7alkyl, or optionally substituted aryl, heteroaryl, arylC1-6alkyl or heteroaryl1-6alkyl; R8 and R9 are independently selected from hydrogen, C1-6alkyl, aryl and arylC1-6alkyl; p is 0-4; and q is 1-4and salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine.